



PATENT  
Attorney Docket No.: 8820-3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of  
Alvin H. Schmaier *et al.*

Group Art Unit:  
1653

Application No.: 09/402,732

Examiner: A. Davenport

Filing Date: December 1, 1999

For: BRADYKININ ANALOGS AS SELECTIVE  
INHIBITORS OF CELL ACTIVATION

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUBMISSION OF SUBSTITUTE SEQUENCE LISTING**

Submitted herewith is a substitute Sequence Listing paper copy. A diskette containing the updated Sequence Listing in computer readable form is also submitted herewith.

Respectfully submitted,  
ALVIN H. SCHMAIER *et al.*

By: *Daniel A. Monaco*  
DANIEL A. MONACO  
Registration No. 30,480  
SEIDEL, GONDA, LAVORGNA  
& MONACO, P.C.  
Suite 1800, Two Penn Center Plaza  
Philadelphia, PA 19102  
Telephone: (215) 568-8383  
Facsimile: (215) 568-5549  
Attorney for Applicants

**CERTIFICATE OF MAILING  
UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

BY

*Katrina Lynn*

DATE:

6/16/00

A

Application No.: 09/462732

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

A